{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:58:57Z","timestamp":1790776737290,"version":"4.1.0"},"reference-count":38,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T00:00:00Z","timestamp":1786838400000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Medical Journal of Australia"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To estimate population\u2010level eligibility for glucagon\u2010like peptide\u20101 receptor agonist (GLP\u20101RA) medications among adults in Australia, according to Therapeutic Goods Administration\u2010approved indications for chronic weight management and secondary prevention of cardiovascular disease in individuals with overweight or obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Type<\/jats:title>\n                    <jats:p>Cross\u2010sectional analysis of data from the Australian Bureau of Statistics 2022 National Health Survey.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting, Participants<\/jats:title>\n                    <jats:p>Non\u2010pregnant adults aged \u2265\u200918\u2009years who were residents of Australia living in a private dwelling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures<\/jats:title>\n                    <jats:p>Total number of adults eligible for GLP\u20101RA medications according to approved indications for chronic weight management and secondary prevention of cardiovascular disease in individuals with overweight or obesity, across subgroups defined by body mass index, weight\u2010related comorbidities and\/or sociodemographic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 39.7% (95% confidence interval [CI], 38.4%\u201341.0%) of adults were eligible for GLP\u20101RA use for chronic weight management, accounting for 7.8 million (95% CI, 7.6\u20138.1 million) individuals. Among those eligible, 2.9 million (95% CI, 2.7\u20133.1 million) adults had no weight\u2010related comorbidities, 3.3 million (95% CI, 3.1\u20133.4 million) adults had one weight\u2010related comorbidity and 1.7 million (95% CI, 1.6\u20131.8 million) adults had at least two weight\u2010related comorbidities. The proportion of adults eligible under this indication varied across clinical and sociodemographic factors. Among those eligible under the chronic weight management indication, up to 338.9 thousand (95% CI, 271.3\u2013406.5 thousand) adults also met the indication criteria for secondary prevention of cardiovascular disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>About 7.8 million Australian adults are eligible to access GLP\u20101RAs for chronic weight management, with up to 338.9 thousand adults also qualifying according to the indication for established cardiovascular disease. This study provides a valuable reference for policymakers to understand the number of adults in Australia who may access GLP\u20101RA medications based on approved indication criteria and under various coverage scenarios.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5694\/mja2.70253","type":"journal-article","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T14:01:12Z","timestamp":1786888872000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimating Eligibility for\n                    <scp>GLP<\/scp>\n                    \u20101 Receptor Agonists for Chronic Weight Management and Cardiovascular Disease in Australia: Cross\u2010Sectional Analysis of National Health Survey Data"],"prefix":"10.5694","volume":"224","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0173-9927","authenticated-orcid":false,"given":"Jasmin","family":"Castrillon","sequence":"first","affiliation":[{"name":"University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Schilling","sequence":"additional","affiliation":[{"name":"University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmala","family":"Thuraisingam","sequence":"additional","affiliation":[{"name":"University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Hii","sequence":"additional","affiliation":[{"name":"University of Melbourne  Melbourne Victoria Australia"},{"name":"St Vincent's Hospital Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Sumithran","sequence":"additional","affiliation":[{"name":"Monash University  Melbourne Victoria Australia"},{"name":"Bayside Health (Alfred Care Group)  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3522-7374","authenticated-orcid":false,"given":"Peter F.","family":"Choong","sequence":"additional","affiliation":[{"name":"University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9708-5308","authenticated-orcid":false,"given":"Michelle M.","family":"Dowsey","sequence":"additional","affiliation":[{"name":"University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cade","family":"Shadbolt","sequence":"additional","affiliation":[{"name":"University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,16]]},"reference":[{"key":"e_1_2_11_2_1","volume-title":"Australian Product Information Wegovy (Semaglutide) Solution for Injection","author":"Australian Government Department of Health, Disability and Ageing Therapeutic Goods Administration","year":"2024"},{"key":"e_1_2_11_3_1","volume-title":"Australian Product Information Ozempic (Semaglutide) Solution for Injection","author":"Australian Government Department of Health, Disability and Ageing Therapeutic Goods Administration","year":"2019"},{"key":"e_1_2_11_4_1","volume-title":"Australian Product Information Mounjaro (Tirzepatide) Solution for Injection","author":"Australian Government Department of Health, Disability and Ageing Therapeutic Goods Administration","year":"2025"},{"key":"e_1_2_11_5_1","volume-title":"Australian Product Information \u2013 Trulicity (Dulaglutide RCH) Autoinjector","author":"Australian Government Department of Health, Disability and Ageing Therapeutic Goods Administration","year":"2025"},{"key":"e_1_2_11_6_1","unstructured":"The Pharmaceutical Benefits Scheme \u201cSemaglutide \u201dhttps:\/\/www.pbs.gov.au\/medicine\/search?term=14844G\u201014846J\u201015311W\u201012075M\u201014163K\u201015322K."},{"key":"e_1_2_11_7_1","unstructured":"The Pharmaceutical Benefits Scheme \u201cDulaglutide \u201dhttps:\/\/www.pbs.gov.au\/medicine\/item\/11364D."},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_2_11_9_1","unstructured":"The Pharmaceutical Benefits Scheme \u201cPharmaceutical Benefits Advisory Committee (PBAC) Meeting Outcomes November 2025 PBAC Meeting \u201dhttps:\/\/www.pbs.gov.au\/industry\/listing\/elements\/pbac\u2010meetings\/pbac\u2010outcomes\/2025\u201011\/pbac\u2010web\u2010outcomes\u201011\u20102025\u2010v2.pdf."},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01356-4"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2400978"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00356-0"},{"key":"e_1_2_11_13_1","unstructured":"Australian Bureau of Statistics (ABS) \u201cDetailed Microdata: National Health Survey ABS DataLab. Findings Based on Use of ABS Data \u201d2022 https:\/\/www.abs.gov.au\/statistics\/health\/health\u2010conditions\u2010and\u2010risks\/national\u2010health\u2010survey\/latest\u2010release."},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/jssam\/smac040"},{"key":"e_1_2_11_15_1","volume-title":"National Health Survey Methodology","author":"Australian Bureau of Statistics","year":"2023"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01200-X"},{"key":"e_1_2_11_20_1","unstructured":"Australian Bureau of Statistics \u201cMicrodata and TableBuilder: National Health Survey \u201dhttps:\/\/www.abs.gov.au\/statistics\/microdata\u2010tablebuilder\/available\u2010microdata\u2010tablebuilder\/national\u2010health\u2010survey."},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.13172"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57349"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574\u2010026\u201001258\u20105"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/cd23-0023"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.70058"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare14020186"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05962-z"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.3399\/BJGP.2025.0610"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.0022"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.16.1523"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23732"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1159\/000538577"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00316-4"},{"key":"e_1_2_11_34_1","volume-title":"Wegovy Launches in Australia","author":"The Royal Australian College of General Practitioners","year":"2024"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2026-597166"},{"key":"e_1_2_11_36_1","unstructured":"IP Australia \u201c2018348929 Semaglutide in Medical Therapy \u201dhttps:\/\/ipsearch.ipaustralia.gov.au\/patents\/2018348929."},{"key":"e_1_2_11_37_1","unstructured":"IP Australia \u201c2017256774 Semaglutide in Cardiovascular Conditions \u201dhttps:\/\/ipsearch.ipaustralia.gov.au\/patents\/2017256774."},{"key":"e_1_2_11_38_1","volume-title":"WHO Guideline on the Use of Glucagon\u2010Like Peptide\u20101 (GLP\u20101) Therapies for the Treatment of Obesity in Adults","author":"World Health Organization","year":"2025"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01375-3"}],"container-title":["Medical Journal of Australia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.5694\/mja2.70253","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.5694\/mja2.70253","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.5694\/mja2.70253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:24:36Z","timestamp":1790774676000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.5694\/mja2.70253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.5694\/mja2.70253"],"URL":"https:\/\/doi.org\/10.5694\/mja2.70253","archive":["Portico"],"relation":{},"ISSN":["0025-729X","1326-5377"],"issn-type":[{"value":"0025-729X","type":"print"},{"value":"1326-5377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2026-03-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70253"}}